1,721,089 research outputs found
Current concepts and future directions for hemato-oncologic diagnostics.
No full textAt present, hemato-oncologic diagnostics is facing dynamic changes. This applies to the exploration and introduction of novel technologies such as next-generation sequencing or digital droplet PCR for myeloid and lymphatic malignancies in laboratory routine, or liquid biopsy for patients with lymphoid malignancies. Targeted therapies such as FLT3 or IDH1/IDH2 inhibitors for acute myeloid leukemia are entering clinical practice. Thus, the demand for hematologic precision diagnostics both at initial diagnosis and during the course of the disease are equally increasing, and a short turn-around time becomes crucial. NGS expands the armamentarium for minimal residual disease diagnostics, but novel questions arise relating to sensitivity, the appropriate time points of this analysis, or the thresholds triggering therapeutic interventions. In this review article, we summarize some of the most relevant current changes and subsequent challenges for diagnostics in various myeloid and lymphatic malignancies. Future directions of hemato-oncologic diagnostics in the next 5-10 years are highlighted
[Molecular biology of malignant lymphomas for non-specialists]
No full textLymphomas comprise a variety of entities with remarkable clinical heterogeneity. This review summarizes the current knowledge on the pathogenesis of major mature B-cell lymphoma subtypes for clinicians working outside the field of hemato-oncology. The understanding of the pathogenesis of lymphomas is linked to the knowledge on normal B-cell differentiation. The clinical diversity is manifested in the different mechanisms involved in lymphomagenesis that include characteristic chromosomal translocations deregulating proto-oncogenes, and inactivation of tumor suppressor genes through deletions and mutations. Gene-expression profiling has dissected certain lymphomas into morphologically indistinguishable, but clinically important subgroups and uncovered pathways suitable for specific therapeutic interventions
Spannende Daten zu aggressiven Lymphomen
No full textAm diesjährigen Jahreskongress der European Hematology Association (EHA) in Wien wurden einige spannende Studien zur Behandlung von aggressiven Lymphomen präsentiert, insbesondere zu bispezifischen Antikörpern, zu einer vielversprechenden neuen CAR-T-Zell-Therapie in der Behandlung des r/r DLBCL sowie neue Daten zum Burkitt- und Mantelzelllymphom
Erstlinientherapie beim diffusen grosszelligen B-Zell-Lymphom: personalisierte Therapie oder alles R-CHOP?
No full text
Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
Full text link
Numerous Hot Topics in Lymphoproliferative Disorders
No full textIn the field of lymphoma, plenty of exciting abstracts were presented at the 2022 meeting of the American Society of Hematology (ASH). Hereby, we will focus on a few highlights, e.g. in entities like classical Hodgkin lymphoma or primary nervous system lymphoma
- …
